Global Survey on the Impact of Decentralized Clinical Trials (DCTs) on Sponsor-CRO Collaborations
The Tufts Center for the Study of Drug Development at the Tufts University School of Medicine is conducting an ambitious global study to characterize and benchmark the impact of decentralized clinical trials (DCTs) on sponsor-CRO collaborations. This is one of the most comprehensive surveys of its kind among clinical research professionals and it will gather critical baselines to compare against future results. We are focused on gaining insights and perceptions on this topic across a wide range of organizations and appreciate your time on this research.
Please click on the link below to complete the survey: Take the Survey
The survey should take approximately 30 minutes of your time. Your responses will be strictly confidential and will only be reported in the aggregate; none of the study findings can be traced back to any individual or organization. A summary report of de-identified, aggregate results will be shared with 10 pharmaceutical companies and contract research organizations (CROs) that funded the study. In appreciation for completing the survey, we’ll send you a summary of the results. Thank you in advance for your participation in this important research effort!
Please complete the survey by March 25, 2022.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
